Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

WLF Questions Ad Division Allegations; “DDMAC Watch” Starts With Strattera

Executive Summary

Direct-to-consumer advertising does not endanger the public health because access to prescription drugs is controlled by physicians, not the public, the Washington Legal Foundation's new advertising regulation watchdog group suggests

You may also be interested in...



FDA Ad Letters Focus On Superiority Claims; Oversight Critiqued On Several Fronts

FDA appears to have shifted the focus of its advertising oversight and is concentrating on superiority claims as opposed to safety issues; the agency also seems to have relaxed the tone of its enforcement, relying more on "untitled" letters than it has in the past

FDA Ad Letters Focus On Superiority Claims; Oversight Critiqued On Several Fronts

FDA appears to have shifted the focus of its advertising oversight and is concentrating on superiority claims as opposed to safety issues; the agency also seems to have relaxed the tone of its enforcement, relying more on "untitled" letters than it has in the past

Peer-Reviewed Uncontrolled Trials Valid For Drug Promotions, WLF Says

Uncontrolled studies published in peer-reviewed journals should be acceptable as promotional information if disseminated with an FDA disclaimer, the Washington Legal Foundation said during FDA's public hearing on direct-to-consumer advertising Nov. 1-2

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS046010

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel